Non-ischemic RVO-ME treated with ranibizumab plus dexamethasone implant achieved superior BCVA improvement versus ranibizumab alone at 3 months and remained significantly better through 9 months.
Adding vamikibart to VEGF inhibition improved visual acuity and retinal anatomy ...